Welcome to the new academic journal OBM Hepatology and Gastroenterology. Recent progress in understanding liver, biliary, pancreatic and gastro-intestinal diseases and their treatments has been observed in the world. OBM Hepatology and Gastroenterology publishes interesting and informative reviews, original articles, and invaluable case reports in this area. We also publish basic research as well as clinical research.
Hepatitis A virus (HAV), HBV, HCV, HDV, and HEV are still a serious issue worldwide. Treatments on these viruses have recently improved. However, liver fibrosis, cirrhosis and hepatocellular carcinoma are still critical conditions. We focus on all of these liver diseases. We also focus on broad-spectrum of gastro-intestinal diseases in this journal.
Please accept our special thanks for choosing to publish in the OBM Hepatology and Gastroenterology. We are looking forward to your submissions for OBM Hepatology and Gastroenterology.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 6.8 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period).
Exploring Novel Treatment Options for Liver Fibrosis: Can Anti-Angiogenics Succeed？
Submission Deadline: March 31, 2019 (Open) Submit Now
Department of Medicine III, Medical Faculty, RWTH Aachen, Germany
ORC ID: 0000-0003-1516-9610
Research gate: www.researchgate.net/profile/Matthias_Bartneck
Research Interests: Innate immunity; cytokines; macrophages; hepatic stellate cells; cancer cells; liver diseases; cellular immunology; nanomedicine; theranostics
About This Topic
Liver fibrosis is promoted by sustained liver injury which frequently leads to portal hypertension which is accompanied by angiogenic processes. Chronic liver diseases represent a serious global health concern and novel strategies to modulate tissue regeneration are urgently needed. The highly motile immune cells represent a valueable target of exploratory therapies, due to their crosstalk with other cell types such as hepatic stellate cells which generate matrix proteins, and with endothelial cells responsible for blood vessel formation. Three types of drugs compete for therapeutic success in fibrosis treatment: 1) nanomedicines, which have enriched the field of drug delivery, specifically by reducing systemic spreading of drugs; 2) next generation biologicals such as bispecific antibodies which may strongly broaden the options to modulate cellular functionality, while 3) small molecules represent a cost-efficient and safe option.
Title：Zinc in liver fibrosis
Author: Kurt Grüngreiff
Affiliation: Clinic of Gastroenterology, City Hospital, Magdeburg, 39130 Magdeburg, Birkenallee 34, Germany
Title: The Autotaxin - Lysophosphatidic Acid axis as a novel therapeutic target for liver fibrosis
Authors: Richell Booijink 1, Ruchi Bansal 1, 2
1. Department of Biomaterials Science and Technology, Technical Medical Centre, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands
2. Department of Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute of Pharmacy, University of Groningen, the Netherlands
Received: 25 February 2019; Published: 31 July 2019; doi: 10.21926/obm.hg.1903030
This review describes our current understanding of the pathogenic role of angiogenesis in chronic liver disease and portal hypertension, emphasizing its involvement not only in the liver but also in extrahepatic complications such as the formation of portosystemic collaterals and increased splanchnic blood flow, and highlighting different [...]
Received: 27 March 2019; Published: 21 June 2019; doi: 10.21926/obm.hg.1902024
Chronic liver diseases affects millions of people worldwide each year. Upon chronic liver injury, a wound healing process ensues, leading to the accumulation of extracellular matrix (ECM) proteins. If the injury persists, this leads to liver fibrosis with excessive scarring of the liver and loss of liver function. Lysophosphatidic acid (LPA [...]
Received: 15 March 2019; Published: 13 June 2019; doi: 10.21926/obm.hg.1902023
Acute and in particular chronic liver disease of viral, alcoholic and non-alcoholic genesis is a large, often unnoticed health hazard around the world. It can lead to cirrhosis and hepatocellular carcinoma (HCC) in the course of decades. Liver fibrosis, conversion of functional parenchyma to connective tissue (scar tissue) as a consequence [...]
NF-κB; the Critical Link between Immune and Metabolic Pathways: Could NF-κB be Used as a Novel Diagnostic and Prognostic Biomarker for Non-Alcoholic Steatohepatitis?
by Athina Chasapi , Konstantinos Balampanis , Anna Tanoglidi , Eleni Kourea , George I. Lambrou , Vaia Lambadiari , Fotios Kalfarentzos , Erifili Hatziagelaki , Maria Melachrinou and Georgia Sotiropoulou-Bonikou
Received: 28 January 2019; Published: 22 May 2019; doi: 10.21926/obm.hg.1902020
(1) Background: A great number of inflammatory mediators and metabolic biomarkers have been shown to contribute to the development and progression of obesity-induced pathologies, including insulin resistance and nonalcoholic fatty liver disease (NAFLD). Many of those mediators are either targets or activators of nuclear factor-κappa B (NF [...]
Received: 20 December 2018; Published: 13 March 2019; doi: 10.21926/obm.hg.1901014
Liver fibrosis leading to cirrhosis and cancer affects millions of people and causes thousands of deaths all over the world. Many signaling pathways could be targeted to block fibrosis but these are not successful. Reviewing recent literature and from our own studies we identified novel target, such as YB-1, which is implicated in inflammation [...]
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.